212 related articles for article (PubMed ID: 9886377)
21. Mucosal and systemic immune responses of mice to tetanus toxoid coadministered nasally with AFCo1.
Romeu B; González E; Del Campo J; Acevedo R; Zayas C; Valdés Y; Cabrera O; Cuello M; Balboa J; Lastre M; Pérez O
Can J Microbiol; 2011 Mar; 57(3):256-61. PubMed ID: 21358768
[TBL] [Abstract][Full Text] [Related]
22. A combination of Flt3 ligand cDNA and CpG oligodeoxynucleotide as nasal adjuvant elicits protective secretory-IgA immunity to Streptococcus pneumoniae in aged mice.
Fukuyama Y; King JD; Kataoka K; Kobayashi R; Gilbert RS; Hollingshead SK; Briles DE; Fujihashi K
J Immunol; 2011 Feb; 186(4):2454-61. PubMed ID: 21242514
[TBL] [Abstract][Full Text] [Related]
23. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
Huang XG; Xu JQ; Ren L; Qiu C; Zhang N; Liu LX; Wan YM; Peng H; Shao YM
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3109-13. PubMed ID: 17313761
[TBL] [Abstract][Full Text] [Related]
24. Neonatal sublingual vaccination with Salmonella proteins and adjuvant cholera toxin or CpG oligodeoxynucleotides induces mucosal and systemic immunity in mice.
Huang CF; Wang CC; Wu TC; Wu KG; Lee CC; Peng HJ
J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):262-71. PubMed ID: 18376242
[TBL] [Abstract][Full Text] [Related]
25. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
[TBL] [Abstract][Full Text] [Related]
26. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity.
Arulanandam BP; O'Toole M; Metzger DW
J Infect Dis; 1999 Oct; 180(4):940-9. PubMed ID: 10479116
[TBL] [Abstract][Full Text] [Related]
27. Oral immunization of interleukin-4 (IL-4) knockout mice with a recombinant Salmonella strain or cholera toxin reveals that CD4+ Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses.
Okahashi N; Yamamoto M; Vancott JL; Chatfield SN; Roberts M; Bluethmann H; Hiroi T; Kiyono H; McGhee JR
Infect Immun; 1996 May; 64(5):1516-25. PubMed ID: 8613355
[TBL] [Abstract][Full Text] [Related]
28. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.
Boyaka PN; Ohmura M; Fujihashi K; Koga T; Yamamoto M; Kweon MN; Takeda Y; Jackson RJ; Kiyono H; Yuki Y; McGhee JR
J Immunol; 2003 Jan; 170(1):454-62. PubMed ID: 12496431
[TBL] [Abstract][Full Text] [Related]
29. Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx.
Abe N; Kodama S; Hirano T; Eto M; Suzuki M
Laryngoscope; 2006 Mar; 116(3):407-12. PubMed ID: 16540899
[TBL] [Abstract][Full Text] [Related]
30. Intranasal IL-12 produces discreet pulmonary and systemic effects on allergic inflammation and airway reactivity.
Matsuse H; Kong X; Hu J; Wolf SF; Lockey RF; Mohapatra SS
Int Immunopharmacol; 2003 Apr; 3(4):457-68. PubMed ID: 12689651
[TBL] [Abstract][Full Text] [Related]
31. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis.
Robinson K; Chamberlain LM; Schofield KM; Wells JM; Le Page RW
Nat Biotechnol; 1997 Jul; 15(7):653-7. PubMed ID: 9219268
[TBL] [Abstract][Full Text] [Related]
32. Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice.
Sun JB; Mielcarek N; Lakew M; Grzych JM; Capron A; Holmgren J; Czerkinsky C
J Immunol; 1999 Jul; 163(2):1045-52. PubMed ID: 10395703
[TBL] [Abstract][Full Text] [Related]
33. Kinetics of mouse antibody and lymphocyte responses during intranasal vaccination with a lipooligosaccharide-based conjugate vaccine.
Hirano T; Jiao X; Chen Z; Van Waes C; Gu XX
Immunol Lett; 2006 Nov; 107(2):131-9. PubMed ID: 17030407
[TBL] [Abstract][Full Text] [Related]
34. Early life T cell responses to pneumococcal conjugates increase with age and determine the polysaccharide-specific antibody response and protective efficacy.
Jakobsen H; Hannesdottir S; Bjarnarson SP; Schulz D; Trannoy E; Siegrist CA; Jonsdottir I
Eur J Immunol; 2006 Feb; 36(2):287-95. PubMed ID: 16385627
[TBL] [Abstract][Full Text] [Related]
35. Deficiency of IL-5 receptor alpha-chain selectively influences the development of the common mucosal immune system independent IgA-producing B-1 cell in mucosa-associated tissues.
Hiroi T; Yanagita M; Iijima H; Iwatani K; Yoshida T; Takatsu K; Kiyono H
J Immunol; 1999 Jan; 162(2):821-8. PubMed ID: 9916704
[TBL] [Abstract][Full Text] [Related]
36. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit.
Isaka M; Yasuda Y; Kozuka S; Miura Y; Taniguchi T; Matano K; Goto N; Tochikubo K
Vaccine; 1998 Oct; 16(17):1620-6. PubMed ID: 9713937
[TBL] [Abstract][Full Text] [Related]
37. Induction of immune responses and prevention of alveolar bone loss by intranasal administration of mice with Porphyromonas gingivalis fimbriae and recombinant cholera toxin B subunit.
Takahashi Y; Kumada H; Hamada N; Haishima Y; Ozono S; Isaka M; Yasuda Y; Tochikubo K; Umemoto T
Oral Microbiol Immunol; 2007 Dec; 22(6):374-80. PubMed ID: 17949339
[TBL] [Abstract][Full Text] [Related]
38. Intranasal immunization with tetanus toxoid and CNF1 as a new mucosal adjuvant protects BALB/c mice against lethal challenge.
Munro P; Flatau G; Lemichez E
Vaccine; 2007 Dec; 25(52):8702-6. PubMed ID: 18035455
[TBL] [Abstract][Full Text] [Related]
39. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity.
Lee SE; Kim SY; Jeong BC; Kim YR; Bae SJ; Ahn OS; Lee JJ; Song HC; Kim JM; Choy HE; Chung SS; Kweon MN; Rhee JH
Infect Immun; 2006 Jan; 74(1):694-702. PubMed ID: 16369026
[TBL] [Abstract][Full Text] [Related]
40. Nasal immunization with tetanus toxoid increases the subsequent systemic dimeric IgA1 antibody response to intramuscular immunization.
Waldo FB
J Clin Lab Immunol; 1991 Mar; 34(3):125-9. PubMed ID: 1667944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
